September 20, 2012 2:08 PM | 1 min read |
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Bank of America has published a research report on Questcor Pharmaceuticals (NASDAQ: QCOR) that said it believes Aetna (NYSE: AET) will continue to review case by case. In the report, Bank of America stated, "QCOR management held a conference call today to clarify the company's interpretation that Aetna's policy change will not be material to Acthar reimbursement. Management stated that most insurers have normally provided coverage for Acthar on a case-by-case basis, including Aetna. The company's support programs and patient targeting have thus far helped get coverage forActhar, despite increasing pushback from insurance providers. Management highlighted a historical success rate of ~85%, including appeals."Bank of America maintained its Buy rating and $45 price objective on Questcor Pharmaceuticals, which is currently trading up 12.75 percent from Wednesday's $26.35 closing price.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.